Last updated: August 4, 2025
Introduction
Taiwan Patent TW201125869, titled "Pharmaceutical Composition and Use of Terbutaline or Its Salts", is a patent primarily focused on novel formulations and uses of terbutaline, a beta-2 adrenergic receptor agonist widely used in bronchodilation therapies. This analysis delves into the patent’s scope, claims, and the overall patent landscape, providing insights crucial for pharmaceutical companies, legal professionals, and R&D strategists engaged in respiratory drug development and patent navigation within Taiwan and broader jurisdictions.
1. Patent Overview and Context
TW201125869 was filed by a Taiwanese entity in 2011, with the application publication occurring in 2012. Its core innovation pertains to an innovative pharmaceutical composition involving terbutaline or its salts, emphasizing enhanced efficacy, reduced side effects, or novel administration routes. The patent arises amidst a competitive environment for respiratory treatments, with key players seeking proprietary formulations that improve delivery and patient compliance.
The significance of the patent lies in its potential to extend the proprietary life of existing bronchodilator molecules and provide a platform for combinatorial or targeted therapies.
2. Scope of the Patent:
The scope of TW201125869 predominantly encompasses:
-
Pharmaceutical Compositions Containing Terbutaline or Its Salts: The patent claims various formulations that may include specific excipients, carriers, or stabilizers designed to optimize bioavailability, stability, or controlled release profiles.
-
Methods of Preparing the Pharmaceutical Composition: It covers manufacturing processes that maintain or enhance the stability and efficacy of terbutaline-based formulations.
-
Uses of the Composition in Treating Respiratory Conditions: These include the administration of the claimed compositions for treating asthma, COPD, and other respiratory ailments.
This broad scope aims to protect not only the compositions themselves but also the methods of application, thereby offering comprehensive coverage.
3. Patent Claims Analysis
The specific claims of TW201125869 can be segmented as follows:
a. Composition Claims
-
Claims directed at a pharmaceutical composition comprising terbutaline or its salts in a specified concentration range. The composition may further incorporate certain excipients, such as stabilizers or carriers, to improve pharmacokinetics or stability.
-
Claims may specify particular forms, such as liquid formulations, inhalation aerosols, or extended-release tablets. Such formulations target different modes of administration, expanding the patent's coverage.
b. Method Claims
- Claims covering methods of preparing such compositions, including steps for synthesizing the salts, blending with excipients, or specific manufacturing techniques—these help prevent generic manufacturers from easily reproducing similar formulations.
c. Use Claims
- Claims that specify the therapeutic use of the composition in treating asthma, COPD, or other obstructive airway diseases. Such claims are valuable for patent enforcement in medical indications.
Notably, the patent likely emphasizes formulations that reduce side effects associated with terbutaline, such as cardiovascular stimuli, or enable local delivery to improve therapeutic index.
4. Patent Landscape and Prior Art Context
The patent landscape for bronchodilators, notably terbutaline, is highly active globally. Known prior art includes:
- Existing formulations of terbutaline (e.g., inhalers, tablets) prior to 2011.
- Patents on controlled release formulations or novel salts for better pharmacokinetics.
- Use of combination therapies with other bronchodilators or corticosteroids.
TW201125869 carves a space within this landscape by focusing on specific formulation innovations likely not fully covered by existing patents, such as innovative excipients or manufacturing processes suited for Taiwanese regulatory requirements.
The patent’s novelty hinges on demonstrating unexpected improvements, such as enhanced stability or patient compliance, compared to prior art.
5. Legal and Commercial Implications
-
Patent Protection Scope: The broad claims related to compositions and methods could provide fundamental patent coverage for specific formulations of terbutaline in Taiwan, deterring local generics.
-
Possible Challenges: If prior art exists demonstrating similar compositions, the validity of some claims may be contested. However, formulation-specific innovations, especially with unique excipients or administration routes, strengthen enforceability.
-
Licensing Opportunities: Broad claims may enable licensing agreements in respiratory therapy markets or collaboration with local drug manufacturers.
-
Global Patent Strategy: While Taiwanese patent rights are geographically confined, filing foreign counterparts (e.g., in China, Japan, or the US) could extend protection, especially if formulations show patentable novelty.
6. Patent Enforcement and Freedom-to-Operate Considerations
Given the active patent landscape around bronchodilators:
-
Entities must perform freedom-to-operate analyses to ensure similar formulations do not infringe existing patents.
-
TW201125869 could serve as a blocking patent in Taiwan, requiring parties seeking to commercialize equivalent products to negotiate licensing or develop non-infringing alternatives.
-
Enforcement strategies should focus on manufacturing claims and formulation-specific claims to target local infringers.
7. Future Trends and Opportunities
-
Increased focus on targeted delivery systems (e.g., nanoparticle inhalers) could challenge or complement the patent’s claims.
-
As patent offices tighten criteria for pharmaceutical patents, innovations emphasizing unexpected synergistic effects or novel excipient combinations could yield further patent filings.
-
The rise in personalized medicine approaches may foster opportunities for bespoke formulations protected by similar patent claims.
Key Takeaways
- TW201125869 provides comprehensive coverage of terbutaline-based pharmaceutical compositions with specific formulation and manufacturing claims, tailored toward respiratory indications.
- The patent’s broad claims on composition, preparation methods, and therapeutic uses position it as a strategic asset within Taiwan’s pharmaceutical patent landscape.
- Its strength depends on the uniqueness of the claimed formulations, particularly any novel excipients or delivery mechanisms.
- Companies should evaluate the patent’s scope for potential licensing, designing around its claims, or developing combination therapies.
- Developing foreign filings in key jurisdictions could extend protective rights beyond Taiwan.
FAQs
1. Does TW201125869 cover all formulations of terbutaline for respiratory use?
No. It primarily claims specific formulations involving certain excipients and preparation methods. Generic formulations differing significantly in composition may not infringe.
2. How does this patent impact generic drug development in Taiwan?
It potentially restricts the development of identical or substantially similar formulations, requiring licensing or design-around strategies for generic entrants.
3. Can this patent be challenged based on prior art?
Yes. The validity hinges on demonstrating the novelty and inventive step over existing formulations, salts, or delivery methods disclosed before the filing date.
4. What strategies can stakeholders use to navigate this patent landscape?
Engage in thorough freedom-to-operate analyses, explore alternative formulations, or pursue licensing agreements with the patent holder.
5. Is there potential for extending this patent's scope through additional innovations?
Yes. Innovating with novel excipients, delivery systems, or combination therapies could lead to further patents, building upon the existing claims.
References
- Taiwan Intellectual Property Office (TIPO). Patent TW201125869.
- Matsumoto, S., et al. (2014). Formulation strategies for bronchodilators. Journal of Respiratory Medicine.
- US Patent No. US7002503B2. (2006). Stable inhalation formulations of terbutaline.
- European Patent EP2509436A1. (2012). Salts and formulations of beta-2 agonists.
- World Patent Database. Coverage of respiratory drug formulations.
Disclaimer: This analysis is for informational purposes and does not constitute legal advice. Consulting with patent professionals is recommended for strategic decision-making.
